Skip to main
INSM
INSM logo

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 31 analyst ratings
Buy
Strong Buy 39%
Buy 55%
Hold 3%
Sell 3%
Strong Sell 0%

Bulls say

Insmed Inc is positioned for substantial growth, with an estimated 500,000 to 1 million diagnosed patients for Mycobacterium Avium Complex lung disease, paired with high misdiagnosis rates that could lead to increased market potential. The company has reiterated its global revenue guidance for ARIKAYCE at $405 million to $425 million for 2025, complemented by the anticipated strong launch of brensocatib, expected to target an $8.2 billion peak sales opportunity in bronchiectasis. Additionally, Insmed's expanded commercial infrastructure, including the addition of 120 sales representatives and further plans for market access enhancement, underlines the company's proactive approach to capitalize on its growing pipeline and potential label expansions.

Bears say

Insmed Inc. faces considerable risks that contribute to a negative outlook on its stock, including potential setbacks in clinical trials and regulatory approvals for its pipeline drugs, which could impede revenue generation. The company reported significant net losses of $235.5 million for the fourth quarter of fiscal 2024 and $913.8 million for the entire fiscal year, raising concerns about its financial sustainability given the substantial investment required for ongoing research and development. Additionally, uncertainties surrounding payer dynamics, the emergence of unforeseen safety signals, and the competitive landscape could further hinder Insmed's ability to successfully commercialize its products and meet its financial obligations.

Insmed (INSM) has been analyzed by 31 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 55% recommend Buy, 3% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Buy based on their latest research and market trends.

According to 31 analysts, Insmed (INSM) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.84, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.84, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.